Navigation Links
Plant-cell-produced technologies-cutting edge approach to bringing solutions to the market

Four months after the world's first vaccine made in plant cells has received regulatory approval in the US, Dow AgroSciences is organising a Science Conference in Brussels on 7 June 2006 in order to share this knowledge with European researchers, scientists, decision-makers and industry representatives.

The pioneering vaccine developed by Dow AgroSciences works against the Newcastle disease virus (NDV) in poultry. The latest technology could be applied quite quickly to other diseases - with avian flu a prime target. This approval represents an innovative milestone for the company and the industry.

The Dow AgroSciences Concert Plant-Cell-Produced System represents a new category of plant-made vaccines. This leading edge technology utilises plant cells instead of whole plants in a secure, bio-contained environment to produce vaccines. Because of this bio-contained production system, concerns and challenges associated with making vaccines in whole plants or food crops are eliminated. The Concert Plant-Cell-Produced System uses only the necessary parts of the disease causing agent to stimulate immunity in a manufacturing process that is totally free of animal components:"Being the first company to ever register a plant-made vaccine is another example of Dow AgroSciences' cutting edge approach to bringing highly novel and differentiated solutions to the market," said Jerome Peribere, Dow AgroSciences' president and CEO.

The conference on 7 June, entitled "Innovations in Biosciences for Animal and Human Health" will highlight major bioscience developments and scientific solutions that could prevent diseases and reduce animal and human health risks in Europe. Dow AgroSciences President and Chief Executive Officer Mr. Jerome A. Peribere will deliver a welcome address. Dow AgroSciences's R&D capability will be presented by Mr. Antonio Galindez, (Dow AgroSciences VicePresicent, Europe, Latin America, Pacific) and Mr. Dan Kittle (Dow AgroSciences Vi cePresicent, Research and Development). Dr. Maurice Lex (European Commission, DG Research) will open discussion on Science Policy and R&D collaboration under the Seventh Framework Programme (FP7) in the area of biosciences for animal and human health.

Two parallel seminars will examine innovative plant-cell technologies and will present the benefit of healthy oils for consumers, agriculture and the food industry. The conference will also explore R&D collaboration under the EU's Seventh Framework Programme (FP7) in the area of biosciences for animal and human health.

Science Conference "Innovations in Bioscience for Animal and Human Health":
Date: 7 June 2006
Time: 08:30-16:00
Location: Renaissance Hotel, Rue du Parnasse 19, 1050 Brussels, Belgium
Admission Free
Online registration and the detailed programme is available at: http://www.isc-europe.com/dasconference/registration.php


'"/>

Source:ISC


Related biology news :

1. Weizmann Institute scientists develop a new approach for directing treatment to metastasized prostate cancer in the bones.
2. MSI releases moleculizer - a new approach to simulation of intracellular biochemical networks
3. Stopping smallpox in its tracks: A new anti-viral approach
4. Building a protein name dictionary from full text: a machine learning term extraction approach
5. Rensselaer researchers develop approach that predicts protein separation behavior
6. Huntingtons cure in flies lays groundwork for broader treatment approaches
7. Results of worlds first gene therapy trial for arthritis show approach safe, feasible
8. Vaginal gel may provide a new approach to HIV prevention
9. Clinical trial to test stem cell approach for children with brain injury
10. Study in Science holds promise for a new approach to drug therapy
11. U-M researchers take new approach to defeating Gram-negative bugs
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/19/2016)... TORONTO , 19 de diciembre de 2016 /PRNewswire/ ... que permitirá el desarrollo acelerado de MSC-1, un anticuerpo humanizado que ... de tumor en 2017, con múltiples sitios previstos a lo largo ... ... en el factor inhibidor de leucemia (LIF), una citoquina pleiotrópica que ...
(Date:12/15/2016)... 15, 2016   WaferGen Bio-systems, Inc. (NASDAQ: ... company, announced today that on December 13, 2016, it ... The Nasdaq Stock Market LLC which acknowledged that, as ... WaferGen,s common stock had been at $1.00 or greater ... compliance with Listing Rule 5550(a)(2) of the Nasdaq Stock ...
(Date:12/12/2016)... , Dec. 12, 2016  Researchers at ... possibilities for graphene by combining the material with ... highly sensitive pressure detector able to sense pulse, ... a small spider.  The research ... can be read here:  http://science.sciencemag.org/content/354/6317/1257 ...
Breaking Biology News(10 mins):
(Date:1/19/2017)... , Jan. 19, 2017 AquaBounty Technologies, ... on enhancing productivity in aquaculture and a majority-owned subsidiary ... that it has completed the listing of its common ... equity subscription from Intrexon. "AquaBounty,s listing on ... will broaden our exposure to the U.S. markets as ...
(Date:1/19/2017)... Yorba Linda, Ca (PRWEB) , ... January 18, ... ... interactive virtual events for tech innovators, engineers, and scientists from around the world, ... Corporate American News. The awards program is based entirely on merit and decided ...
(Date:1/19/2017)... ... 19, 2017 , ... DaVita Clinical Research (DCR), ... and device development, and Prism Clinical Research , a leader in providing ... Verified Clinical Trials (VCT) has been selected by both companies as an ...
(Date:1/19/2017)... Md. , Jan. 18, 2017  Northwest Biotherapeutics, ... developing DCVax® personalized immune therapies for operable and inoperable ... Bosch , Chief Technical Officer of NW Bio, will ... January 19, 2017, at the Hyatt Regency Hotel in ... Bosch will chair the session entitled "New Therapeutic Approaches ...
Breaking Biology Technology: